Flavio Ribichini

Prof. Flavio Ribichini

Cardiovascular Division, University of Verona, Italy
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
GPGabriele Pesarini
Gabriele Pesarini
RSRoberto Scarsini
Roberto Scarsini
CZCarlo Zivelonghi
Carlo Zivelonghi
APAnna Piccoli
Anna Piccoli
AGAlessia Gambaro
Alessia Gambaro
FRFlavio Ribichini
Flavio Ribichini
Background—: Aortic valve stenosis may influence fractional flow reserve (FFR) of concomitant coronary artery disease by causing hypertrophy and reducing the vasodilatory reserve of the coronary circulation. We sought to investigate whether FFR values might change after valve replacement. Methods and Results—: The functional relevance of 133 coronary lesions was assessed by FFR in 54 patients with severe aortic valve stenosis before and after transcatheter aortic valve implantation (TAVI) during the same procedure. A linear mixed model was used to verify the interaction of TAVI effect with the FFR values. No significant overall change in FFR values was found before and after the aortic valve stenosis removal (0.89±0.10 versus 0.89±0.13; P =0.73). A different trend in FFR groups (positive if ≤0.8; negative if >0.8) was found after TAVI ( P for interaction 50 worsened after TAVI (0.84±0.12 versus 0.82±0.16; P =0.02), whereas FFR values in arteries with mild lesions (percent diameter stenosis <50) tended toward improvement after TAVI (0.90±0.07 versus 0.91±0.09; P =0.69). Functional FFR variations after TAVI changed the indication to treat the coronary stenosis in 8 of 133 (6%) lesions. Conclusions—: Coronary hemodynamics are influenced by aortic valve stenosis removal. Nevertheless, FFR variations after TAVI are minor and crossed the diagnostic cutoff of 0.8 in a small number of patients after valve replacement. Borderline coronary lesions might become functionally significant after valve replacement, although FFR-guided interventions were infrequent even in patients with angiographically significant lesions.

24 April 2025 in European Heart Journal
Verified
Journal Article
Open access
SFSimone Fezzi
Simone Fezzi
BSBruno Scheller
Bruno Scheller
BCBernardo Cortese
Bernardo Cortese
FAFernando Alfonso
Fernando Alfonso
RJRaban Jeger
Raban Jeger
PSPatrick Serruys
Patrick Serruys
The Drug Coated Balloon Academic Research Consortium project originated from the lack of standardization and comparability between studies using drug-coated balloons in the treatment of obstructive coronary artery disease. This document is a collaborative effort between academic research organizations and percutaneous coronary intervention societies in Europe, the USA, and Asia. This consensus sought to standardize study designs and endpoints for clinical trials involving drug-coated balloons, including defining angiographic, intravascular, and non-invasive imaging methods for lesion assessment, alongside considerations for post-revascularization pharmaco-therapy. The concept of ‘blended therapy’, which advocates for combining device strategies, is also discussed. This paper delineates study types, endpoint definitions, follow-up protocols, and analytical approaches, aiming to provide consistency and guidance for interventional cardiologists and trialists.

1 August 2017 in The American Journal of Cardiology
Verified
Journal Article
Closed access
CZCarlo Zivelonghi
Carlo Zivelonghi
GPGabriele Pesarini
Gabriele Pesarini
RSRoberto Scarsini
Roberto Scarsini
MLMattia Lunardi
Mattia Lunardi
APAnna Piccoli
Anna Piccoli
FRFlavio Ribichini
Flavio Ribichini

19 November 2019 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
MLMattia Lunardi
Mattia Lunardi
RSRoberto Scarsini
Roberto Scarsini
GVGabriele Venturi
Gabriele Venturi
GPGabriele Pesarini
Gabriele Pesarini
MPMichele Pighi
Michele Pighi
FRFlavio Ribichini
Flavio Ribichini
Background: Management of coronary artery disease in patients undergoing transcatheter aortic valve implantation is uncertain. Fractional flow reserve ( FFR ) has never been clinically validated in aortic stenosis. The study aim was to analyze the clinical outcome of FFR ‐guided revascularization in patients undergoing transcatheter aortic valve implantation. Methods and Results: Patients with severe aortic stenosis and coronary artery disease at coronary angiography were included in this retrospective analysis and divided in 2 groups: angiography guided (122/216; 56.5%) versus FFR ‐guided revascularization (94/216; 43.5%). Patients were clinically followed up and evaluated for the occurrence of major adverse cardiac and cerebrovascular events at 2‐year follow‐up. Most lesions in the FFR group resulted negative according to the conventional 0.80 cutoff value (111/142; 78.2%) and were deferred. The FFR ‐guided group showed a better major adverse cardiac and cerebrovascular event–free survival compared with the angio‐guided group (92.6% versus 82.0%; hazard ratio, 0.4; 95% CI , 0.2–1.0; P =0.035). Patients with deferred lesions based on FFR presented better outcome compared with patients who underwent angio‐guided percutaneous coronary intervention (91.4% versus 68.1%; hazard ratio, 0.3; 95% CI , 0.1–0.6; P =0.001). Conclusions: FFR guidance was associated with favorable outcome in this observational study in patients undergoing transcatheter aortic valve implantation. Randomized trials are needed to investigate the long‐term effects of FFR ‐guided revascularization against angiographic guidance alone in patients with aortic stenosis.

6 August 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ABAndrea Bottardi
Andrea Bottardi
GPGuy F A Prado
Guy F A Prado
MLMattia Lunardi
Mattia Lunardi
SFSIMONE FEZZI
SIMONE FEZZI
Gabriele PesariniGabriele Pesarini
Gabriele Pesarini
FRFlavio Ribichini
Flavio Ribichini
Despite significant goals achieved in diagnosis and treatment in recent decades, coronary artery disease (CAD) remains a high mortality entity and continues to pose substantial challenges to healthcare systems globally. After the latest guidelines, novel data have emerged and have not been yet considered for routine practice. The scope of this review is to go beyond the guidelines, providing insights into the most recent clinical updates in CAD, focusing on non-invasive diagnostic techniques, risk stratification, medical management and interventional therapies in the acute and stable scenarios. Highlighting and synthesizing the latest developments in these areas, this review aims to contribute to the understanding and management of CAD helping healthcare providers worldwide.

1 August 2010 in The American Journal of Medicine
Verified
Journal Article
Closed access
FRFlavio Ribichini
Flavio Ribichini
MGMariastella Graziani
Mariastella Graziani
GGGiovanni Gambaro
Giovanni Gambaro
PPPaolo Pasoli
Paolo Pasoli
MPMichele Pighi
Michele Pighi
CVCorrado Vassanelli
Corrado Vassanelli